head game initi outperform
de-risk regulatori pathway larg
erratum origin version note publish earlier today incorrectli list
target price result miscalcul net cash correct target price
assumpt remain unchang
initi coverag outperform rate
tp satsuma specialti biopharmaceut compani develop dri powder
intranas inhal formul dihydroergotamin mesyl dhe use combin
proprietari drug deliveri devic treat acut migrain adult posit satsuma
believ path regulatori approv de-risk drug/devic
differenti see upsid commerci larg address market
potenti fda approv de-risk view long-term experi dhe
year prior fda approv dhe formul de-risk regulatori process
essenti valid scientif rational provid substanti guidanc
phase trial design expect next year phase emerg trial data read posit
share trade upward clinic trial updates/execut throughout next year
differenti drug/devic design believ differenti drug formul
devic design could lead better patient experi improv uptake/
complianc ultim translat higher commerci potenti
larg market support multipl competitor despit potenti competit
landscap believ market support sever compet drug conserv
estim could launch unadjust peak sale
 satsuma could strateg takeout target given migrain focu recent
alder/lundbeck deal highlight valu address migrain opportun
believ satsuma could potenti acquisit larger biopharma compani de-
risk path approv differenti drug/design attract valuat
valuat risk target price deriv dcf use wacc
price market risk
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc clinical-stag biopharmaceut
compani develop novel therapeut product acut treatment
migrain
blue sky scenario per share assum probabl
success po acut migrain result fda approv
assum better expect sale lower competit
result greater market penetr blue sky valuat base
dcf driven wacc termin growth
grey sky scenario per share assum po
acut migrain fda approv drug blue sky
valuat base dcf driven wacc termin
growth essenti valu compani cash scenario
 close
tabl content
lower develop risk long-term experi dhe
model view acut migrain market
risk commerci multipl competitor
proprietari migrain survey larg market new therapi drug rel
undifferenti far
potenti look prior deal space
initi coverag outperform rate
target price satsuma san francisco-bas clinical-stag specialti
biopharmaceut compani focus develop acut migrain medic
compani sole asset phase clinic develop dri powder intranas
inhal formul dihydroergotamin mesyl dhe use combin proprietari
drug deliveri devic treat acut migrain adult estim could gener
unadjust peak sale posit satsuma believ
phase emerg data read de-risk upcom data
posit demonstr improv efficaci compar liquid dhe broader
activ compar triptan current standard care drug display reason
safeti profil less pk variabl vs liquid dhe commerci perspect
believ differenti design formul could improv
commerci target larg address market high familiar
physician dhe market iv formul year could lead better uptak
look central nervou system landscap believ satsuma could
good strateg fit larger biopharma compani given recent purchas alder
pharmaceut lundbeck acquisit colucid lilli
acut migrain market larg enough support multipl player despit
crowd space see risk commerci due multipl undifferenti
competitor develop competitor could potenti take share
acut migrain popul howev remain posit compani due upsid
impli equiti valuat base de-risk regulatori pathway conserv
assumpt account signific competit believ acut migrain market
larg enough triptan-refractori patient support sever abort therapi
differenti data phase emerg studi could drive upsid tp
demonstr rel higher efficaci better safeti profil versu competitor
differenti drug/devic design like improv patient experi enhanc
commerci market histor challeng novel migrain
medicin previous difficult commerci chronic migrain drug ajovi
emgal sale under-perform consensu expect acut migrain drug
plagu devic failur believ novel drug formul
devic design could lead better patient experi improv uptake/
complianc ultim translat higher commerci potenti view
conveni administ intranas therapi vs iv dhe single-us dose vs
multipl migran dose furthermor novel powder formul vs liquid migran
provid enhanc adhes nasal mucosa may lead consist dose
turn consist respons look manufactur aspect powder formul
reportedli provid longer shelf-lif easier storag requir compar liquid dhe
formul also believ simpl devic design compar predecessor
lend better commerci lower likelihood manufactur failur overal
attribut give us greater confid could meaning differenti
well-posit take signific market share acut migrain market
larg address market consider rate reoccurr standard care
triptan creat opportun us migrain market repres
patient around estim experi acut migrain current standard
care acut migrain triptansa drug class market drug sinc associ
consider patient dissatisfact side effect profil cardiac diseas
contraind despit drug efficaci patient triptan experi higher
migrain reoccurr medic overus headach chronic use accord
channel check current literatur nearli one-third patient triptan refractori
experi migrain reoccurr view creat signific opportun
address triptan-refractori patient acut set assum
posit captur share first-lin set sumatriptan given potenti
challeng payer approv ahead triptan howev inroad make
set could add addit upsid estim
lower development commerci risk given familiar dhe physician
believ de-risk given formul dhe
market sinc lend better understand efficaci safeti toler
discuss kol physician familiar iv liquid intranas
migran formul believ extens physician experi dhe clinic
practic preced prior regulatori approv valid phase trial design
discuss kol increas confid ultim gain regulatori
approv gain traction market
enhanc efficaci compar iv dhe broader activ potenti lower
headach reoccurr compar triptan believ demonstr
differenti pk profil show less variabl faster time onset longer durat
action compar liquid intranas migran dhe target greater rang
receptor compar sumatriptan like contribut longer durat therapi
lead lower reoccurr rate view display potenti improv
efficaci liquid dhe could drive market leader triptan-
refractori acut migrain popul compar sumatriptan prior trial iv/im dhe
show lower rate migrain reoccurrenceon import measur patient
satisfact accord physician spoke treat migrain given data
could potenti see lower headach reoccurr compar triptan phase
trial believ may use case triptan conserv
estim market penetr set
accept safeti profil in-lin dhe formul lower pk variabl
compar migran larger trial need confirm safeti higher dose phase
trial demonstr accept safeti toler line market
formul dhe believ risk seriou safeti issu phase trial lower
given long-term experi dhe howev believ larger phase trial need
confirm higher dose safe
proprietari migrain survey suggest opportun base larg unmet
market attribut meet physician prefer conduct proprietari migrain
survey better understand current market takeaway survey includ triptan
still prefer therapi patient triptan-refractori physician
hesit prescrib triptan due perceiv cardiovascular risk level relief safeti profil
fast onset import factor decid therapi newer therapi
develop gepant lasmiditan perceiv significantli differenti
triptan efficaci safeti view survey support view could
take share market given larg refractori popul rel undifferenti
competitor develop lower perceiv risk cv risk vs triptan furthermor
possess attribut fast onset action sustain effect similar safeti
 satsuma could good strateg fit larger partner given migrain
focu view recent purchas lundbeck
highlight valu address migrain opportun transact
infrequ smaller transact focus novel asset technolog much
common see satsuma good strateg fit larger biopharma compani given
reason valuat although past year biohaven report
press bloomberg possibl takeout target believ high valuat may
limit attract overal believ satsuma could potenti acquisit candid
larger biopharma compani de-risk path approv differenti drug/design
attract valuat
price target price deriv dcf use wacc
termin growth rate forecast cash flow believ discount
rate reflect risk associ research-and-development-focus biotechnolog
compani earli stage commerci first approv asset assign
termin growth free cash flow assum satsuma small molecul asset
retain signific valu beyond patent expir commerci exclus yet believ
compani on-going invest success replac
revenu long term
risk view risk includ litig revenu result meet exceed
expect intellectu properti key patent deem invalid overturn us ou
author clinic development clinic trial may neg pipelin asset may
produc expect result regulatori fda ema may delay fail approv
satsuma investig product commerci sale
near-term outlook near term expect share trade upward clinic trial
updat execut could see interim data look emerg efficaci trial
although compani disclos interim data present
expect final phase emerg efficaci data next year also expect
updat regard safeti studi could includ detail surround satsuma
discuss fda safeti studi base case assum
month studi necessari approv
long-term outlook long-term remain posit satsuma compani
develop differenti drug/devic larg market market competitor
view path regulatori approv de-risk given familiar experi
dhe market year commerci greater challeng believ
drug well posit take market share simplifi devic improv patient
satisfact limit manufactur failur despit potenti multipl competitor
lasmiditan rimegep etc believ market larg enough multipl player
therefor anticip satsuma could take reason share acut migrain
popul context view satsuma consider acquisit candid
given de-risk regulatori pathway clean stori high unmet need recent
lundbeck/ald deal could improv investor interest space satsuma could
strateg fit larg biopharma compani seek add late-stag bolt-on asset
could gener immedi revenu long term anticip signific upsid
commerci phase assum approv begin gener revenu
 outlook target price rate satsuma incorpor adjust
anticip transact acquisit howev believ could strateg rational
acquisit satsuma compani establish migraine/headache/neurosci
franchis hypothet transact believ satsuma could acquir
premium line migrain transact sinc
figur satsuma stock price index sinc ipo vs xbi etf
adjust revenu ep migrainephas efficaci studi report top-line migrainephas safeti studi migrainenda migraineestim commerci launch late charl martineau univers toronto octob
price target per share base sum-of-the-part discount cash flow
dcf analysi figur assum discount rate fulli dilut share
tax rate believ discount rate reflect risk associ
research develop focus specialti biopharmaceut compani earli stage
commerci first approv asset assign termin growth free cash flow
assum satsuma small molecul asset retain signific valu beyond
patent expir commerci exclus yet believ compani on-going
invest success replac revenu long term
base sotp dcf driven valuat sale acut migrain base
case assum probabl success po higher standard rang
phase asset believ de-risk given formul
dhe market year lend better understand efficaci
safeti toler result valu risk-adjust po
combin unalloc corpor expens net cash sotp
dcf valu satsuma figur
st corporatenet stsafisc year end decemberdiscount analysi million except per share adjust us valu growth rate unalloc unalloc adjust us sale adjust us opex tax tv total stock base increas /decreas capit equiti share current free fulli dilut share adjust us price hard unallocated/corpor last price hard charl martineau univers toronto octob
dcf sensit analysi includ sensit analysi help support valuat
look differ wacc tvgr termin valu growth rate figur assum
neg flat growth tv still see dcf valuat higher
current share price
figur dcf sensit wacc tvgr varianc price per share
valuat blue sky scenario assum probabl success
po acut migrain result fda approv assum better-than-
expect sale lower competit result greater market penetr
blue sky valuat base dcf driven wacc termin growth
grey valuat grey sky scenario assum po acut
migrain fda approv drug blue sky valuat base dcf
driven wacc termin growth essenti valu compani cash
scenario
clinic development risk satsuma mid-stag clinic
develop sever signific risk exist complet clinic trial includ
limit trial enrol delay efficaci safeti concern poorli
design studi inadequ endpoint insuffici power
regulatori risk satsuma expect file new drug applic nda
end fda may approv regulatori file potenti requir costli re-
trial discontinu program altogeth fda could requir potenti confirmatori
trial costli time-consum regulatori delay reject
neg impact valu satsuma share
commerci risk new entrant marketplac could add competit pressur
marketplac exist competitor may produc drug prove
efficaci and/or safer factor lead lower adopt rate
price risk conserv estim pipelin drug price base
compani report transcript feedback signific chang estim
price compar actual price could consider impact revenu forecast
valu satsuma share drug price current key topic polit debat
price could affect polici chang
market risk histor volatil sector unpredict
market forc exist could disrupt equilibrium investor may bearish
biotechnolog potenti drug price legisl may choos put
capit work sector clariti provid possibl
lower develop risk long-term
experi dhe
believ potenti fda approv de-risk provid upsid
develop process eventu launch given long-term experi prior fda
approv dhe believ valid dhe mechan well-understood safeti
present lower barrier potenti fda approv base phase data
demonstr improv efficaci compar liquid dhe broader activ compar
triptan current standard care reason safeti profil less pk variabl vs
satsuma also address drawback prior dhe formul
differenti design formul could improv commerci simpl devic
big improv complic devic ultim scrap due
problem manufactur devic failur powder formul appear
improv prior liquid intranas formul migran due better mucos adhes
therebi lead improv efficaci local intranas administr may help limit side
effect compar system administr iv/im dhe oral therapi
develop given demonstr evid nausea phase trial
current treatment paradigm suggest opportun improv migrain
episod disord affect us patient annual character sever headach
gener associ nausea sensit light sound episod last sever
hour time multipl episod monthli diseas sever limit patient
report result lost work time one-third case accord
report integr benefit institut highli preval world-wid still
treatment option patient suffer diseas own pathophysiolog
mani neurolog disord diseas mechan typic multifactori
challeng target pharmacolog fortun recent advanc moder
success migrain prevent includ anti-calcitonin gene-rel peptid
cgrp drug amgen aimovig teva ajovi lilli emgal howev new drug
abort treatment acut migrain slow evolv standard care
moder sever acut migrain triptansa drug class market drug sinc
associ consider patient dissatisfact refractori sever patient iv
formul dihydroergotamin dhe commonli use although usual given
hospit inconveni patient given current landscap see signific
opportun new player enter market acut set includ satsuma
could fill high unmet need current treatment fall short signific
opportun exist fill gap current treatment option fail view
need conveni effect treatment acut migrain low seriou
manag side effect look across current treatment landscap see figur
therapi meet compon criterialeav open
gain portion market
figur therapi acut migrain
new england journal medicin credit suiss
triptan mainstay migrain treatment year effect
patient drug class associ higher migrain reoccurr seriou side
effect chronic use studi winner et al triptan mg sc demonstr
headach reoccurr within hour compar subcutan mg sc dhe
headach reoccurr key factor patient dissatisfact per discuss kol
compar target dhe sumatriptan figur see dhe target
serotonin receptor broadli ad adrenerg dopamin target contrast
sumatriptan target much narrow rang result drug
dissoci target rapidli result shorter durat action antonaci et
al shorter half-lif triptan propos mechan increas migrain
triptan also one common caus medication-overus headach
kristoffersen et al type chronic headach develop continu use headach
medic believ one biggest drawback triptan commonli
result drug discontinu antonaci et al furthermor report cardiac risk includ
contraind patient coronari arteri diseas import consider
prescrib report literatur downplay signific safeti charl et
al channel check suggest physician still hesit prescrib triptan due
perceiv cv risk despit dhe also potenti cardiac side effect overal
perceiv cv risk shorter half-lif limit use case triptan yet still believ
triptan remain therapydict mainli payer given low cost triptan
classspecif treatmentsreport effectscommon seriou aecommenttriptansalmotriptan sumatriptan zolmitriptanpain relief hr pain-fre hr tight medication-overus headachecontraind cadergotsmigran dhe nasal spray dhe injectionpain relief hr dizzi contraind cad pvd patientscgrp receptor antagonist oral rimegep ubrogepantpain-fre hr relief hr hr diclofenac ibuprofenpain relief hr gastric ulcersantiemet agentschlorpromazin metoclopramid prochlorperazinepain relief hr restless dyston charl martineau univers toronto octob
figur comparison receptor target activitydh vs sumatriptan
dihydroergotamin dhe good altern triptan use histor limit
mode administr higher incid nausea dhe usual reserv triptan-
refractori patient hospit emerg set via iv im administr
conveni intranas liquid formul migran market year
variabl efficaci limit drug commerci success per channel check
migrain specialist believ variabl migran efficaci due partli
potenti drug breakdown due liquid formul subtherapeut dose decreas
nausea common dhe-bas drug advers event devic issu
includ glass mix liquid furthermor kol mention migran devic
complic requir devic prime potenti multipl dose although
state patient mostli abl learn administr process anoth drawback dhe
increas incid nausea like result prolong action broader
rang target howev nausea far pronounc inject formul
compar intranas
treatment includ acetaminophen nsaid gener less effect
achiev pain-fre effect compar triptan dhe therapi gener
reserv mild migrain furthermor advers effect nsaid caus gastric
given drawback market dhe iv im migran formul believ
prime potenti deliv winner acut migrain market
intranas powder provid conveni mode administr unlik iv dhe provid
higher serum concentr translat better efficaci compar migran discuss
detail later look side effect kol indic major patient
concomitantli take anti-nausea medic ondansetron metoclopramid dhe
control nausea view issu nausea unlik limit factor
kol state patient gener well-control anti-nausea medic
believ major patient would prefer take dhe addit anti-nausea drug
migrain better control overal believ well posit take
signific share acut market conveni form dhe improv efficaci
manag side effect
efficaci gener well-understood given long histori dhe market
dhe market drug year provid consider bodi evid
experi manag side effect accord channel check gener believ
dhe proven efficaci acut migrain side effect reason mitig
kol also state physician comfort prescrib drug use
limit refractori patient discuss previous use case dhe limit due iv
administr conveni form migran shown mix efficaci view
debat whether drug improv current form dhe
rather prove efficaci dhe believ differenti base
differenti pk profil show less variabl faster time onset longer durat
action compar liquid intranas migran dhe
phase trial demonstr lower pk variabl faster sustain plasma
concentr phase trial includ two-part studi involv healthi patient
single-cent single-dos open-label studi figur highest dose mg
select move part includ crossov trial migran
base data figur display faster onset sustain
respons compar migran unsurprisingli dhe im inject faster
sustain although direct inject rather intranas administr
look vs migran see reach therapeut
concentr ng/ml per satsuma within minut migran reach
therapeut level trial onset action highlight kol key driver
patient satisfact therapeut effect within first minut optim
trial reach peak concentr within minut compar minut
migran
equal import longer sustain plasma concentr vs migran
demonstr greater area-under-curv auc higher auc translat
lower pk variabl drug maintain greater plasma dhe concentr
therapeut rang ng/ml contrastingli migran peak near therapeut threshold
maintain high enough plasma concentr like contribut mix
respons seen clinic practic furthermor believ longer sustain respons
could potenti improv headach reoccurr view differenti
migran given faster sustain dhe plasma concentr translat
better efficaci
reason safeti profil in-lin dhe formul lower dose larger
phase trial need confirm safeti higher dose phase trial
demonstr accept safeti toler mg dose in-lin
market formul dhe figur trial patient take highest
dose mg show incid treatment emerg advers effect teae
compar im dhe migran report gener mild
nasal congest nasal discomfort believ risk seriou safeti issu phase
trial lower given long-term experi dhe howev larger phase trial
need confirm higher dose safe
phase trial size well-suit potenti fda approv satsuma receiv fda
guidanc design phase emerg triala studi patient
random either mg mg placebo see figur trial endpoint
primari endpoint freedom pain bothersom symptom
photophobia phonophobia nausea hour post-treat
power respect satsuma state freedom pain power delta
symptom discuss kol physician agre
co-primari endpoint chosen clinic relev gold
standard migrain trial
secondari endpoint sustain freedom pain need
rescu mediat pain relief avoid relaps function quality-of-lif
endpoint patient global impress
accord compani initi design base fda publish guidelin link fda
guidelin develop acut treatment migrain drug recent fda
agre propos emerg studi design singl efficaci studi could
suffici support potenti nda file channel check kol agre trial
well posit potenti fda approv efficaci safeti maintain accord
satsuma use headach diari import help ensur trial patient actual
migrain compani note prior competitor trial use headach diari
may confound result non-migrain patient includ overal believ trial
properli design appropri endpoint power particularli given fda guidanc
takeaway prior dhe trial
treatment emerg disorderslacrim disordersabdomin disordersvessel puncture/inject site system disorderstast thorac mediastin disordersnas charl martineau univers toronto
follow phase emerg trial expect satsuma conduct
safeti studi use select dose emerg trial
trial like need regulatori file provid evid safeti
product administ multipl dose recal phase emerg trial singl dose
forese outsiz risk trial believ drug safe
evidenc phase trial note requir core reason
compani file approv emerg trial late compani yet
disclos design trial
satsuma could leverag prior data/studi manufactur file nda
earlier possibl ad year market exclus compani could
potenti file new drug applic nda fda pathway typic less
frequent use regulatori pathway hybrid tradit nda novel drug
abbrevi new drug applic anda gener drug pathway permit
manufactur seek approv drug key element activ ingredi
similar previous approv version could permit satsuma includ prior data
dhe essenti could allow compani gain fda approv without perform
longer term studi typic need new novel drug save cost could
potenti bring drug market sooner furthermor could grant year
market exclus recal new novel drug via full nda usual elig year
exclus gener drug via anda usual receiv month note
extens ip protect asset least us patent provid
bulk exclus protect pend patent could extend
differenti drug/devic design like improv patient experi believ
simpl devic design could lead better patient experi improv
complianc ultim translat higher commerci potenti pocket-s devic
provid compact conveni devic self-administ figur devic
requir prime assembl furthermor powder formul reportedli less
sensit temperatur light allow patient greater conveni portabl
simplifi devic design could help prevent manufactur issu plagu
fail competitor like simpl design devic contain
move part complic machineri approach satsuma provid
straightforward manufactur process compar failur acquir allergan
background file nda
inhal dhe drug/devic extens machineri part see figur map receiv
three crl supplier defici issu canist fill unit
devic actuat map unabl resolv issu program eventu
stop end believ satsuma devic better approach could potenti
limit supplier issu devic failur
figur devic designa complic approach seriou
nda expect file assum launch figur
satsuma guid nda file expect assum phase
safeti studi requir file approv near term enrol complet
phase emerg efficaci studi expect anticip interim
look data given alreadi acceler develop pathway note compani
receiv feedback fda trial design path nda file forese
major delay development process assum posit result given fda guidanc
combin takeaway prior nda file dhe formul
model view acut
larg address market posit view satsuma potenti
commerci market migrain recur headach affect approxim
adult us stoke et al debilit headach translat direct cost
estim worker often prevent achiev full product happi
goldberg et al make matter wors patient current receiv sub-optimal care
accord migrain preval prevent studi patient report still
repres larg address market opportun model satsuma need captur
small portion acut migrain market gener upsid stock appreci
recent launch novel migrain product less stellarbut believ
differenti easili take share due like good efficaci like less
payer barrier conveni dose patient
acut migrain model assumpt begin us popul conserv
estim us citizen suffer migrain annual basi arriv million
patient see figur market model estim migrain patient
chronic day month assum million migrain patient diagnos
seek treatment estim acut diagnos patient find relief
triptan account triptan failur remov chronic suffer arriv
elig patient popul million estim elig patient popul
seek abort therapi nonsteroid anti-inflammatori drug nsaid leav
plan independ commerci us potenti partner ou
model us sale per discuss manag compani plan commerci
us time state interest possibl ou partner could potenti
gener greater interest satsuma acquisit given recent alder/lundbeck deal
recal alder plan commerci us sought ou partner
end lundbeck decid outright purchas alder
figur acut migrain market model
greatest risk commerci stage long-term
commerci success larg depend patient access turn uptak
believ satsuma need target primari care physician famili medicin intern
medicin addit neurologist per channel check proprieti migrain survey
discuss later primari care physician less awar dhe compar neurologistsa
potenti hurdl commerci key factor affect market opportun
averag monthli use singl use net price studi note
patient educ recogn premonitori symptom prior acut attack may lead better
efficaci outcom charl et al sever risk commerci success
includ whether product patient-friendli market face
less clinic risk dhe new molecul one key barrier percept dhe
specialti product side effect anoth signific risk need educ patient
practition differenti clinic aspect powder dhe
fiscal year end sale us unadjust success po adjust growth acut acut patient day month elig patient seek treatment patient seek treatment abort migrain migrain switch triptan switch therapi treat round market price price price net number monthli acut migrain migrain month per migrain per patient us sale charl martineau univers toronto
conserv preval price assumpt in-lin current anti-cgrp per
manag guidanc assum annual net price line anti-cgrp
drug estim annual price increas gross-to-net discounta higher
discount reflect competit migrain space also assum averag acut
migrain per month per patient impli averag per year take account
averag monthli migrain annual net price estim singl use price
conserv estim patient compli treatment
patent protect least although intellectu properti ip
includ composit matter given dhe alreadi market satsuma own exclus
world-wide licens issu us patent issu foreign patent patent portfolio
extend pend patent formul dosag devic method treatment
pend us patent estim expir issu us
patent expect expir pend patent
jurisdict expect expir assum launch
current patent provid least year protect gener drug-devic combin
histor difficult generic may provid addit barrier
risk commerci multipl
market larg enough support multipl player despit crowd space
see risk commerci due multipl undifferenti competitor
develop competitor could potenti take share acut migrain
popul view reflect conserv sale patient estim howev
remain posit compani due upsid impli equiti valuat
base de-risk regulatori pathway reasonable/attain sale account
signific competit view market acut migrain larg triptan-
refractori patient could support sever abort therapi highlight differenti
data phase emerg studi could drive upsid tp
demonstr rel higher efficaci better safeti profil versu competitor given
avail data remain conserv view market
prefer therapi yet play although make case
could drive consider uptak believ possess commerci attribut
could increas market penetr includ high familiar physician dhe market
iv formul year drug/devic design enhanc patient experi less
drug degrad look conveni differenti could envis case
intranas prefer oral therapi base better portabl suggest
discuss kol howev attribut yet play market could
potenti neglig highlight sever potenti competitor acut migrain
space rel risk
migran unlik pose competit threat given mix efficaci
underwhelm sale migran commerci avail liquid dhe intranas
administr bausch health compani first launch migran post
million sale sinc initi launch migran perform well commerci
market multi-step administr process led inconsist efficaci outcom often
leav patient dissatisfi consensu estim show forecast sale declin
despit commerci avail expect minim threat first migran
demonstr mix efficaci unreli respons mani patient commerci
perspect migran requir devic prime potenti multipl dose complic
administr limit uptak migran requir four spray administ
minut reach full dose incorrect administr pertain multipl dose lead
less effect outcom compar single-dos devic overal lacklust sale
point poor user experi declin market share
repres modest threat efficaci improv prior liquid dhe
formul problem devic product degrad may still exist impel
neuropharma new formul liquid dhe dose intranas administr
similar migran expect complet phase trial year earlier clinic data show
distinct migran phase trial result improv
bioavail compar migran signal potenti better efficaci base
higher dhe plasma exposur could viabl threat limit potenti peak
market share late stage clinic data show improv efficaci migran
howev note issu relat inconsist respons may still persist even
display improv efficaci clinic trial devic may requir assembl prime sever
part patient unabl properli prime devic liquid dhe degrad
could inconsist respons overal potenti earlier market arriv posit phase
clinic data potenti devic prime assembl highlight modest competit threat
figur comparison versu
lasmiditan pose consider competit threat improv safeti
lower cv risk earlier time market dizzi could limit uptak lasmiditan
select agonist develop administ oral current await nda
review lasmiditan serotonin agonist less like induc vasoconstrict like
dhe triptan result lasmiditan could theoret safer patient
cardiovascular risk factor dizzi common side effect lasmiditan
demonstr phase samurai spartan trial studi patient take lasmiditan
demonstr higher incid dizzi tepper et al trend also evid phase
trial lasmiditan patient experienc dizzi farkkila et al overal
potenti earlier commerci conveni oral administr repres consider
figur phase trial design dhe emerg oral treatment
oral gepant cgrp receptor antagonist could greater competit risk given
potenti lower cv risk oral conveni gepant calcitonin gene-rel
peptid cgrp receptor antagonist use abort therapi number fda
approv monoclon antibodi target cgrp receptor migrain prevent includ
aimovig erenumab ajovi fremanezumab emgal galcanezumab howev note
prevent migrain therapi approv abort therapi therefor
impact market unless futur trial complet clinic trial oral gepant use
abort therapi shown posit clinic efficaci look figur highlight
recent clinic data avail oral cgrp current statu launch time
asid conveni oral administr anoth advantag oral gepant may
reduc potenti cardiovascular advers effect compar triptan dhe
product note oral gepant rais liver toxic concern lead discontinu
telcagep overal conveni oral administr posit clinic trial data
figur comparison phase efficaci data emerg oral treatment
ultim success like depend commerci brand prefer
note opinion larg de-risk clinic regulatori mileston
consider import commerci identifi
potenti competitor within space made conserv market penetr
estim reflect larg number investig acut therapi emphas four key
aspect feel bolster commerci process improv
formul potenti lower headach recurr rate easi administr
ubrogepantrimegepantatogepanttelcagepantcompanyabbviebiohavenabbviemerckmechanismcgrp antagonistcgrp antagonistcgrp antagonistcgrp antagonistcurr statusfil nda/blaphas recent trial dataphas achiev ii phase armsubrogep mg placebo rimegep placeboatogep mg qd mg qd mg qd mg bid mg bid mg bidn/aprimari pain free hr w/ bothersom symptom absent hr pain free hr w/ bothersom symptom absent hr chang baselin mean monthli migrain day wk n/aadvers eventsnausea dizzi neither report frequenc tract infect nausea nausea fatigu constip nasopharyng urinari tract infect discontinu due liver toxic concern twice daili charl martineau univers toronto
improv formul compar iv powder formul conveni
administ may lead better complianc powder formul may allow
easier storag potenti longer shelf-lif open liquid dhe use
migran must use thrown away within hour lastli
powder formul provid enhanc adhes nasal mucosa may lead
consist dose
potenti lower headach recurr rate dhe target wider rang
receptor result longer durat action may key driver lower
recurr rate patient
easi administr requir prime non-invas procedur
may appeal patient manag assert fewer part
requir assembl user-friendli design allow easier
administr potenti establish consum prefer
singl dose stss proprietari devic deliv powder dhe singl dose multi-
step dose may lead inconsist dose patient outcom overal
anticip four key aspect relat support market
new therapi drug rel
undifferenti far
proprietari migrain survey suggest signific opportun
take market share given larg triptan-refractori popul attribut
meet physician prefer assess current state migrain market us
conduct survey board certifi physician follow practic
neurology/headach specialist primari care select physician
current practic us varieti treatment set privat practic
academic/teach hospit community-bas practic averag primari
care physician report total practic made migrain patient
compar neurologist
triptan prescrib abort therapi mild moder migrain
patient follow nsaid expect physician indic triptan nsaid
prefer abort therapi mild moder migrain patient see figur
averag prescrib triptan mild moder acut patient compar
neurologist therapi open respond write-in beta blocker
common respons
figur prescript habit mild moder acut migrain patient
similarli triptan prescrib moder sever patient find
moder sever headach patient triptan also preval first line
therapi acut migrain see figur survey triptan prescrib
neurologist base case estim posit take share
moder sever acut migrain market rather mild moder popul
howev could see addit upsid satsuma layer sale less sever patient
figur prescript habit moder sever acut migrain patient
around one-third patient refractori triptan highlight opportun
mani patient respond well triptan despit prefer
therapi acut patient find relief triptan neurologist
find patient respond triptan see figur size market
assum patient start triptan use second line
abort therapi discuss previous conserv estim triptan
refractori consider lower estim seen survey
figur acut migrain patient find adequ relief triptan
respond triptan
physician hesit prescrib triptan due perceiv cv risk
common view triptan perceiv greater cardiovascular risk cv ergot
abort therapi literatur subject mix perceiv risk
concret effect triptan prescript find prescript habit among
neurologist diverg matter acut patient prescrib triptan
despit cv risk compar neurologist see figur
patient prescrib triptan due cv risk compar neurologist
discuss previous migrain specialist talk view perceiv triptan cv risk
overst highlight mani still view risk signific therefor satsuma
could potenti make inroad primari care market reluct prescrib
figur acut migrain patient prescrib triptan despit cv risk
prescrib triptan due cv risk
prescrib triptan due cv risk
physician prefer abort drug highest level relief follow safeti
profil fast onset action survey level relief rank
import factor influenc prescrib decis emphas highest weight averag
score figur safeti profil fast onset rank highli import
factor consid prescrib medic least import factor evid
lowest weight averag rank tablet form oral dissolv tablet
figur weight averag score respect prescript factor
mitig bothersom symptom
cover payor
durat relief
level relief
physician percept efficaci safeti develop abort therapi gepant
lasmiditan particularli differenti triptan physician indic
abort therapi effect figur lasmiditan rank highest averag
score follow triptan score ubrogep rimegep oral triptan
receiv rel similar rank therapi receiv averag score
safeti physician show percept rel undifferenti triptan
develop treatment figur
figur weight averag score respect drug
figur weight averag score respect drug
safe neutral safe
potenti look prior
deal space
satsuma reason fit potenti acquisit candid given migrain
focu target price rate satsuma incorpor adjust
anticip transact acquisit howev believ would strateg rational
acquisit satsuma compani establish migraine/headache/neurosci
 transact infrequ figur smaller transact focus
novel asset technolog much common hypothet transact believ
satsuma could acquir premium in-lin migrain transact
view recent purchas lundbeck
highlight valu address migrain opportun also highlight
acquisit colucid map premium given lead asset time
indic acut migrain
figur activ mute though smaller transact common
map acquir
forecast satsuma incom statement balanc sheet statement
figur incom statement balanc sheet found figur
statement cash flow found figur
incom statement million except per adjust us includ royalti unadj unadj incom incom loss tax expens tax incom averag share basic averag share average share use calcul dilut dilut cs charl martineau univers toronto octob
balanc asset equival incl expens current issuanc current equip stockhold equitycurr term current term conting convert prefer equitycommon paid-in comprehens stockhold liabil stockhold charl martineau univers toronto octob
figur satsuma statement flow
activ net compens asset expens cash use oper activ purchas properti invest cash use invest activ borrow net issuanc issuanc common stock cash use financ decreas increas cash cash cash equival begin cash equival end charl martineau univers toronto octob
author report evan seigerman would like acknowledg work matthew
terwelp md lauren luca adrian garcia equiti research associ credit suiss
john kollin presid chief execut offic
prior cofound john founder manag
director parnassu advisor llc provid strategi business/corpor
develop servic biopharmaceut compani sinc enter biopharmaceut
industri john serv c-level senior execut role multipl public
renovi athena neurosciences/elan immunex john earn mba
univers virginia darden school engin degre duke univers
prior join tom chief offic protagonist
therapeut inc sinc enter biopharmaceut industri tom serv
c-level manag role multipl public privat biopharmaceut compani
monogram bioscienc tom earn mba univers california lo angel
anderson graduat school manag ba pomona colleg
prior join detlef serv c-level senior execut role
multipl public privat biopharmaceut compani includ armetheon sorbent
relypsa ilypsa alza mirav schwarz pharma sinc enter biopharmaceut
industri detlef involv develop drug variou indic
area urolog pain manag oncolog renal cardiovascular diseas detlef
receiv medic degre doctor rheinisch westflisch technisch
hochschul aachen germani
iwashima vice presid head oper
prior join serv sinc varieti manag
role shin nippon biomed laboratori extens background nasal drug
deliveri year experi develop snbl nasal drug deliveri platform
technolog product candid role snbl encompass oper product
develop regulatori affair busi develop intellectu properti manag
earn engin degre north carolina state univers also
research area nasal flow comput fluid dynam
robert schultz vice presid head
prior join rob earli member senior leadership
team pearl acquir astrazeneca led global project
pearl tripl combin mdi sinc enter pharmaceut industri rob
also led develop initi multipl inhal product includ advair
serev flovent ventolin azmacort insulin mdi product serv role
increas respons glaxosmithklin acquir abbott rob earn
biochemistri degre dartmouth colleg
shannon strom ph vice presid head regulatori affair
prior join shannon member global
regulatori leadership drug develop team pearl acquir
astrazeneca develop multipl metered-dos inhal mdi product includ
bevespi aerospher pearl tripl combin mdi recent work global
regulatori role roivant scienc sinc begin biopharmaceut industri career
shannon involv develop drug variou indic
area neurolog psychiatri pain manag oncolog respiratori diseas shannon
earn undergradu degre biolog duke univers doctor degre
pharmacolog univers north carolina
click enter text
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
